BRAF and skin neoplasm: Moreover, the BRAFV600E and vemurafenib story has made crystal clear how critical it is that the pathways are understood in the smallest detail to overcome potential problems such as, in this case, the BRAF-paradox; inhibition of B-Raf with vemurafenib caused skin tumors in normal skin by inhibitor-induced refitting of the Raf pathway [100].